SCHEMBL19854479

SCHEMBL19854479

C/C=C(\C)C(=O)N(C)c1ccc(C2CCC(C3CCC(CCCCC)CC3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.42
▸ MAPT P10636 4/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ SPHK1 Q9NYA1 5/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ ESR2 Q92731 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ POLQ O75417 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CCR2 P41597 1/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19855024 0.97 CYP2C9 (0.44) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19855032 0.88 CYP2C9 (0.43) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19856043 0.88 CYP2C9 (0.43) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19856037 0.87 CYP2C9 (0.42) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19856035 0.87 CYP2C9 (0.42) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19855046 0.85 SPHK1 (0.46) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19854471 0.85 CYP2C9 (0.42) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19854478 0.85 CYP2C9 (0.42) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL19854933 0.84 CYP2C9 (0.45) CYP2C9MAPTALDH1A1LMNASPHK1
SCHEMBL20370487 0.83 CYP2C9 (0.43) CYP2C9MAPTALDH1A1LMNASPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 CYP2C9 3761/4885MAPT 1073/4885ALDH1A1 3826/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 CYP2C9 3761/4885MAPT 1073/4885ALDH1A1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback